Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)

Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14) - Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000092

Enrollment

108

Registered

2005-08-30

Start date

1993-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

previouly untreated advanced stage Hodgkin lymphoma (stage II, III, IVy)

Interventions

polychemotherapy, raiotheraoy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Biopsy-proven Hodgkin lymphoma (2) Clinical stage II, III or IV (3) PS 0-3 (ECOG) (3) No severe organ dysfunction (4) Age < 70 (5) Previously untreated (6) With evaluable lesions (7) Written informed consent

Exclusion criteria

Exclusion criteria: 1.severe comorbidity (e.g. severe infectious disease, heart failure, respiratory dysfunction, hepatic failure, liver cirrhosis, renal failure, active peptic ulcer, insulin dependent diabetes mellitus 2. other active neoplasms 3. psychological disease 4. expected survival ; less than 3 months 5. Pregnant women 6. Past history of myocardial infarction 7. Positive for HTLV-1

Design outcomes

Primary

Measure	Time frame
complete response rate (%CR+%Cru), progression-free survival	—

Secondary

Measure	Time frame
toxicity, 5-year surivival, prognostic foctor	—

Countries

Japan

Contacts

Public ContactMichinori Ogura, MD, PhD

JCOG9305 Coordinating Office Department of Hematology, Nagoya Daini Red Cross Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026